FORUM Pharmaceuticals
Closed portfolio snapshot
According to ClinicalTrials.gov-derived indexes, FORUM Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count).
FORUM Pharmaceuticals: 13 sponsored US clinical trials, none currently recruiting.
FORUM Pharmaceuticals sponsors 13 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 10 completed. 6 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Schizophrenia, with 3 trials.
Top-decile sponsor footprint
FORUM Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
10 of 13 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (76.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
13 total, page 1 of 1
Study to Assess the Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Effects of EVP-6308 and the Potential of EVP-6308 to Affect the PK Properties of the Antipsychotic Regimen in Subjects With Schizophrenia Currently Receiving Stable Treatment With up to 2 Atypical Antipsychotics
NCT02037074
Study of the Safety and Clinical Effects of 2 Doses of EVP-6124 in Subjects With Alzheimer's Disease Who Complete Study EVP-6124-024 or EVP-6124-025
NCT02004392
Study of EVP-6308 to Assess the Dose- and Concentration-dependent Displacement of [18F]MNI-659 by EVP-6308
NCT02001389
Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease
NCT01969123
Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease
NCT01969136
A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
NCT01714713
Safety, Tolerability, Pharmacokinetics of EVP-0962 and Effects of EVP-0962 on Cerebral Spinal Fluid Amyloid Concentrations in Healthy Subjects and in Subjects With Mild Cognitive Impairment or Early Alzheimer's Disease
NCT01661673
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
NCT01714661
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
NCT01716975
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
NCT01073228
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
NCT00968851
Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's Disease
NCT00766363
Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Schizophrenia
NCT01556763
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 3 |
| Phase 3 | 6 |
Therapeutic Areas
How the FORUM Pharmaceuticals archive is shaped
13 indexed studies, none listed as recruiting (0% open); 10 completed (77%).
Phase mix: 6 late (III/IV) vs 7 early (I/II) (balanced across stages).
Top condition: Schizophrenia (3 trials), 3 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
FORUM Pharmaceuticals: archived-pipeline peers nationwide
Peers matched on 13 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
FORUM Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 13 archived trials
- Adaptimmune · 13 trials · 0% recruiting
- Agennix · 13 trials · 0% recruiting
- Akili Interactive Labs · 13 trials · 0% recruiting
- Alumis · 13 trials · 8% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this FORUM Pharmaceuticals page
13 registered trials is a research-attention snapshot, not an endorsement of FORUM Pharmaceuticals or any single study.
- None of FORUM Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Schizophrenia is the condition FORUM Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Schizophrenia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
FORUM Pharmaceuticals pipeline card: 13 registered trials from official public datasets.Report a data error.